Bayer (BAYRY) HealthCare Pharmaceuticals was granted FDA orphan designation for a treatment of non-small cell lung cancer harboring epidermal growth factor receptor mutations, and/or human epidermal growth factor receptor 2 activating mutations, according to a post to the agency’s website.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- Bayer price target raised to EUR 26 from EUR 22 at Berenberg
- Bayer could stop selling Roundup weedkiller over legal risks, Reuters says
- Bayer expects improved performance from 2026 onwards
- Bayer sees FY25 core EPS EUR 4.50-EUR 5.00 on currency-adjusted basis
- Bayer sees FY25 sales roughly at prior-year level
Questions or Comments about the article? Write to editor@tipranks.com